Menu Search
Equities

Satellos Bioscience Inc

MSCL:TOR

Satellos Bioscience Inc

Actions
Basic MaterialsPrecious Metals and Mining
  • Price (CAD)0.75
  • Today's Change-0.06 / -7.41%
  • Shares traded351.19k
  • 1 Year change+57.89%
  • Beta1.5831
Data delayed at least 15 minutes, as of Nov 22 2024 20:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The 2 analysts offering 12 month price targets for Satellos Bioscience Inc have a median target of 1.10, with a high estimate of 1.20 and a low estimate of 1.00. The median estimate represents a 35.80% increase from the last price of 0.81.
High48.1%1.20
Med35.8%1.10
Low23.5%1.00

Earnings history & estimates in CAD

On Nov 13, 2024, Satellos Bioscience Inc reported 3rd quarter 2024 losses of -0.05 per share. This result was in line with the consensus of the 3 analysts following the company and under-performed last year's 3rd quarter results by 66.67%.
The next earnings announcement is expected on Mar 31, 2025.
Average growth rate-25.60%
Satellos Bioscience Inc reported annual 2023 losses of -0.18 per share on Mar 27, 2024.
Average growth rate-44.20%
More ▼

Revenue history & estimates in CAD

iCo Therapeutics Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
iCo Therapeutics Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.